Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Crisis And Violence In Mumbai: Experiences From A Centre For Vulnerable Women And Children
In this week"s open access journal PLoS Medicine, Nayreen Daruwalla and
generic viagra online
Altair Therapeutics Reports Successful Completion Of Phase I Study Of Inhaled AIR645
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, reported results from its phase I study evaluating the safety, tolerability and pharmacokinetics of its lead product, once-weekly inhaled AIR645, in healthy volunteers. AIR645 is a non-steroidal dual inhibitor of cellular responses to interleukin (IL)-4 and IL-13, cytokines that play a critical role in development and progression of asthma, rhinitis and other allergic disorders. Results presented today at the 2009 International Conference of the American Thoracic Society (ATS) within the Mini-Symposium "New Treatment Approaches for Asthma and Allergy" showed that inhaled AIR645 was safe, well tolerated and had dose-dependent exposure in the airways. These results demonstrate the potential of AIR645 as a convenient once-weekly treatment for asthma and other respiratory disorders. Later this year, Altair plans to initiate a phase II efficacy study in patients with asthma.
News of the day
Long-Term Medtronic Device Registry First To Show How Implantable Heart Devices Work In Real-World Clinical Practice
The first results from the Medtronic Inc., (NYSE: MDT) OMNI Study were released at Heart Rhythm 2009, the annual congress of the Heart Rhythm Society, revealing that one out of six patients with implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillators (CRT-Ds) to prevent sudden cardiac arrest (SCA), received potentially life-saving medical therapy - either in the form of anti-tachycardia pacing (ATP) or a shock for dangerously fast heart rhythms - within a period of two years following their implant. Further, the study showed that patients received therapy at similar rates, regardless of whether they meet current medical society guidelines.
Cardiovascular

Three Organizations Form Alliance To Address Global Malnutrition

"Three internationally known organizations based in St. Louis - the Donald Danforth Plant Science Center, the Washington University School of Medicine and St. Louis Children"s Hospital" - have entered into a partnership, known as the Global Harvest Alliance (GHA), which aims to "create inexpensive, nutritionally complete food to help the world"s hungry and undernourished," the AP/Google.com reports. Alliance researchers will focus on several of the most successful approaches used to combat malnutrition and attempt to further enrich foods already used to fight it. "In addition, the alliance aims to help testing and distribution of crops genetically modified to boost nutritional content. They hope to provide the crops cheaply to farmers to produce more nutritious foods," writes the AP/Google.com (Taylor, 7/29). Mark Manary, a professor of pediatrics at Washington University School of Medicine and a member of the Donald Danforth Plant Science Center, will lead GHA, according to a Washington University in St. Louis release. Manary"s "peanut butter-based ready-to-use therapeutic food (RUTF) for the treatment of severe acute malnutrition has consistently resulted in 90 percent recovery rates in research and operational projects," according to the release (7/27). According to KWMU, "Manary said malnutrition causes about half of all child deaths" (Wolf, 7/28) AP/Google.com reports that apart from addressing malnutrition, GHA will try to identify more sustainable solutions. "Prevention is always better than a cure," Manary said. Roger Beachy, president of Danforth, said, "This is not a magic bullet. It"s a part of the puzzle to helping people be healthier and have a better life." According to Larry Beach, a biotech scientist with USAID not directly involved with GHA, says there is some suspicion of biotechnology and "skepticism about providing more nutrition through food because that"s not the way it"s been done in the past." According to Beach, "[o]ne of the big problems in helping to make improvements in nutrition is the integration of what needs to be done," he said (7/29). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009